medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2009, Number 6

<< Back Next >>

Rev Mex Urol 2009; 69 (6)

Mn-superoxide dismutase (Mn-SOD) expression levels and prostate specific antigen correlation in prostate cancer

Floriano-Sánchez E, Cárdenas-Rodríguez N, Castro-Marín M, Flores-Terraza J, Torres-Salazar JJ

Language: Spanish
References: 37
Page: 259-267
PDF size: 449.59 Kb.


ABSTRACT

In addition to its antioxidant function, manganese superoxide dismutase (Mn-SOD) plays a role in tumor suppression in different neoplasms, including prostate tumors. Greater Mn-SOD expression in prostate cancer (CaP) tissue than in benign prostate hyperplasia (BPH) tissue in stromal cells as well as glandular tissue has been demonstrated. Prostate specific antigen (PSA), even levels below 4.0 ng/mL, is known to be a CaP risk marker and only 8% of the cancer-free population presents with higher PSA levels. The present study analyzes Mn-SOD expression levels in CaP tissue and correlates them with PSA levels.
Materials and methods: PSA level was retrieved from case records and Mn-SOD expression levels were determined by immunohistochemistry.
Results: Of the 26 diagnosed cancer tissue samples, no correlation was found between Mn-SOD expression levels and PSA levels. Data was analyzed using Pearson correlation with an index of 0.04182 and p-value was P=0.4163.
Conclusions: There was no correlation between Mn-SOD expression levels and PSA levels in the cancer tissue studied.


REFERENCES

  1. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003 Dec;170(6 Pt 1):2444-52.

  2. Fleshner N, Trachtenberg J. New developments and controversies in androgen deprivation therapy for advanced prostatic carcinoma. A.U.A. Update Series. Lesson 12.

  3. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000 Oct 1;14(19):2410-34.

  4. Alcatraz Asencio A. Alteraciones genéticas en el CaP. Instituto de Investigación Básica August Pi Sunyer 2004;5-38.

  5. MacDonald NJ, Steeg PS. Molecular basis of tumour metastasis. Cancer Surv 1993;16:175-199.

  6. Clark LC, Combs GF Jr, Turnbull BW. Study of selenium and vitamin E for cancer prevention in patients with carcinoma of prostate. Nat Can Inst 2005.

  7. Dirección general de vigilancia epidemiológica. Disponible en: www. dgepi.salud.gob.mx.

  8. Harrison´s Principios de Medicina Interna. Dennis L Kasper, Eugene Braunwald, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo, J. Larry Jameson, Kurt J. Isselbacher, Ed. Mc Graw-Hill. 2005.

  9. Iesaki T, Gupte SA, Kaminski PM, Wolin MS. Inhibition of guanylate cyclase stimulation by NO and Bovine arterial relaxation to peroxynitrite and H2O2. Am J Physiol 1999 Sep;277(3 Pt 2):H978-85.

  10. Laskin DL, Sunil V, Guo Y, Heck DE, Laskin JD. Increased nitric oxide synthase in the lung after ozone inhalation is associated with activation of NF-kappa. Environ Health Perspect 1998 Oct;106 Suppl 5:1175-8.

  11. Mögel M, Krüger E, Krug HF, Seidel A. A new coculture-system of bronchial epithelial and endothelial cells as a model for studying ozone effects on airway tissue. Toxicol Lett 1998 Aug;96-97:25-32.

  12. Cross CE, Halliwell B, Borish ET, Pryor WA. Oxygen radicals and human disease. Ann Intern Med 1987 Oct;107(4):526-45.

  13. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006 May 11;5:14.

  14. Hu Y, Rosen DG, Zhou Y. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem 2005 Nov 25;280(47):39485-92.

  15. de Kok JB, Verhaegh GW, Roelofs RW. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002 May 1;62(9):2695-8.

  16. Sarmina Y, Resnick MI. Obstructive uropathy in patients with benign prostatic hyperplasia. J Urol 1989 Apr;141(4):866-9.

  17. St. Clair D, Wan XS, Kuroda M, Vichitbandha ST, Suchida E, Urano M. Supresion of tumor metastasis by manganeso superoxide-dismutase is associated with reduced tumorigenicity and elevated fibronectin. Oncol Rev 1997;4:753-757.

  18. Martin RC, Hughes K, Doll MA. Method for determination of (-102C>T) single nucleotide polymorphism in the human manganese superoxide dismutase promoter. BMC Genet 2004 Dec 14;5(1):33.

  19. Roehrbon CG, Mc Connell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: PC Walsh, AB Retik ED. Vaughan Jr, AJ Wein. Vol. 15. Ed. Philadelphia.WB Saunders Co. 2002. 1270 –1330.

  20. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003 Mar-Apr;16(2):95-101.

  21. Carter HB. Prostate cancers in men with low PSA levels--must we find them? N Engl J Med 2004 May 27;350(22):2292-4.

  22. Mytrle JF, Klimley PG, Ivor L, Bruni JF. Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. Advances in cancer diagnostics. San Diego: Hybritech Inc, 1986.

  23. Mytrle JF. Normal levels of prostate-specific antigen (PSA), clinical aspects of prostate cancer. Assessment of New Diagnostic and Management Procedures. Proceedings of a workshop of the Prostate Cancer Working Group of the National Cancer Institute’s Organ Systems Program, New York: Elsevier, 183.

  24. Catalona WJ, Smith DS, Ratliff TL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991 Apr 25;324(17):1156-61.

  25. Catalona WJ, Partin AW, Slawin KM. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998 May 20;279(19):1542-7.

  26. VanLersel MP, Witjes WP, De la Rosette JJ. Prostate specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis.. Br J Urol 1995 Jul;76(1):47-53.

  27. Crawford E, DeAntoni E, Ross C. The role of prostate-specific antigen in the chemoprevention of prostate cancer. J Cell Biochemist Suppl 1996;25:149-155.

  28. Yang QF, Sakurai T, Shan L. Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer. J Human Genet 2000;45(6):363-6.

  29. Catalona WJ, Smith DS, Wolfert RL. Evaluation of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995 Oct 18;274(15):1214-20.

  30. Kahlos K, Anttila S, Asikainen T. Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma. Am J Respir Cell Mol Biol 1998 Apr;18(4):570-80.

  31. Ryo I, Satoshi A, Motohiro I. Expression of manganese superoxide dismutase in esophageal and gastric cancers. J Gastroenterol 1998 Dec;33(6):816–22.

  32. Mc Cord JM, Fridovich I. An enzyme-based theory of obligate anaerobiosis: the physiological function of superoxide dismutase. Proc Nat Acad Sci 1971;68(5);1024-27.

  33. Zhao Q, Simpson LG, Driscoll KE. Chemokine regulation of ozone induced neutrophil and monocyte inflammation. Am J Physiol 1998 Jan;274(1 pt 1):L39-46.

  34. Zentella M, Saldaña Y. Papel fisiológico de los radicales libres. Biol Educ Bioq 1996;15:152-161.

  35. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000;279(6):L1005–28.

  36. Thon WF, Gadban F, Truss MC. Prostate-specific antigen density--a reliable parameter for the detection of prostate cancer? World J Urol 1996;14(1):53-8.

  37. Thompson IM, Pauler DK, Goodman PJ. Prevalence of prostate cancer among men with a prostate-specific antigen level ‹ or =4.0 ng per milliliter. N Engl J Med 2004 May 27; 350(22):2239-46.




2020     |     www.medigraphic.com